HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elissavet Vervessou Selected Research

Rituximab (Mabthera)

5/2022Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
9/2021Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
8/2021Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Elissavet Vervessou Research Topics

Disease

4B-Cell Lymphoma (Lymphoma, B Cell)
05/2022 - 01/2021
1Non-Hodgkin Lymphoma (Lymphosarcoma)
05/2022

Drug/Important Bio-Agent (IBA)

3Rituximab (Mabthera)FDA Link
05/2022 - 08/2021
1Monoclonal AntibodiesIBA
05/2022
1polatuzumab vedotinIBA
08/2021
1Bendamustine HydrochlorideFDA Link
08/2021

Therapy/Procedure

2Radiotherapy
09/2021 - 01/2021